[Geneva – 22 May 2018]
GARDP is pleased to announce a £1m investment from the UK Government’s Department of Health and Social Care. This funding will contribute towards accelerating the development of a new treatment for drug-resistant gonorrhoea with a primary focus on enabling sustainable access in low- and middle-income countries.
[Geneva – 22 May 2018]
PLOS, in collaboration with GARDP, is delighted to announce the launch of the Antimicrobial Resistance (AMR) Channel during the World Health Assembly, Geneva. This new channel offers the AMR research community access to the latest research, as well as commentaries, blogs, news, and discussions that span science, research and development, policy, and public health in the fight against AMR.
[26 April 2018]
Funding will support studies on new treatments for neonatal sepsis and drug-resistant STIs in South Africa
[22 February 2018]
Manica Balasegaram, co-author of the ‘Unavailability of old antibiotics threatens effective treatment for common bacterial infections’, comments following publication in The Lancet Infectious Diseases.
[25 January 2018]
The Global Antibiotic Research and Development Partnership (GARDP) welcomes DRIVE-AB’s acknowledgement that a combination of ways to apply and attract financial investments in research and development (‘push and pull incentives’) are required to effectively stimulate antibiotic innovation. We support many of their recommendations.
[Cape Town – 8 November 2017]
Non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) and the Global Antibiotic Research and Development Partnership (GARDP) today opened a new liaison office in Cape Town, South Africa.
[19 September 2017]
A report – “Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including Mycobacterium tuberculosis” – launched today by the World Health Organization (WHO) shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
[Berlin – 4 September 2017]
Germany hosts pledging event for GARDP, a new initiative to develop new antibiotic treatments
Germany together with a number of countries and foundations today pledged EUR 56.5 million to help develop new treatments to fight against antibiotic resistance, during a fundraising event for the Global Antibiotic Research and Development Partnership (GARDP), hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research.
[Geneva – 7 July 2017]
Joint WHO and GARDP/DNDi News Release: Data from 77 countries show that antibiotic resistance is making gonorrhoea – a common sexually-transmitted infection—much harder, and sometimes impossible, to treat.
[Boston, Geneva – 6 July 2017]
First partnering deal for newly-created GARDP with Entasis includes access and stewardship strategy to tackle drug-resistant gonorrhea
Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks to a new partnership between the not-for-profit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. The announcement comes as the World Health Organization (WHO) releases alarming new data today showing that of 77 countries surveyed across the world, more than 60% report resistance to the last-resort treatment for gonorrhea.
[Deutsch] [Français] [Português]
[Geneva, Switzerland – September 22, 2016]
The Drugs for Neglected Diseases initiative (DNDi) is pleased to announce financial support from the Swiss Government to the DNDi-WHO joint initiative Global Antibiotic Research & Development Partnership (GARDP) launched earlier this year.
[24 May 2016 – Geneva, Switzerland]
A new joint initiative by the WHO and DNDi that seeks to develop new antibiotic treatments to address the major public health threat of antimicrobial resistance announced today that it has received the necessary seed funding to build its scientific strategy, initial R&D portfolio, and start-up team.